A blood test can detect Alzheimer's with 94.5% accuracy, according to a study

Early detection of Alzheimer's through blood tests represents a hope in the medical approach to one of the most prevalent neurodegenerative diseases on the planet. The World Health Organization (WHO) projects that the number of people living with dementia will increase from the current 57 million to 139 million in the year 2050. This accelerated growth places Alzheimer's, which already accounts for between 60% and 70% of dementia diagnoses, at the center of global health priorities. Faced with this scenario, recent research highlights an advance that promises to drastically modify the diagnostic strategies, anticipating the possibility of personalized and less invasive interventions. The development of blood tests capable of detecting early signs of Alzheimer's definitively moves away from the category of hypothesis and approaches the field of what is concretely applicable.

A clinical study conducted in Spain on a cohort of 200 patients over 50 years of age, all with symptoms, verified the effectiveness of the p-tau217 protein as a blood biomarker for the identification of the disease. The results, published in Journal of Neurology, revealed that the diagnostic accuracy of doctors increased from 75.5% by incorporating only clinical evaluation, to a remarkable 94.5% after adding the p-tau217 protein data. This finding opens a path towards diagnosis from a simple blood sample, with a direct impact on clinical practice. The work was led by Jordi A. Matías-Guiu, from the Complutense University of Madrid.

We recommend reading:Obesity significantly accelerates the appearance of Alzheimer's, according to a new study

A study conducted in Spain on a cohort of 200 patients over 50 years of age showed that the p-tau217 protein in blood allows the disease to be identified with an accuracy of 94.5 percent, notably improving the accuracy compared to traditional clinical evaluation (Illustrative Image Infobae)

Researchers not only measured the accuracy of the diagnoses, but also the safety of the professionals in their decisions. The blood analysis caused a change in the diagnosis in about one in four patients. Those who, under traditional clinical criteria, received a presumption of Alzheimer's, turned out to have other conditions, while the test allowed to identify cases that were initially attributed to normal aging. The doctors' confidence in their diagnosis increased from 6.90 to 8.49 on a 10-point scale. Innovation is not limited to the initial diagnosis, but extends to all phases of cognitive decline. The p-tau217 protein showed efficacy in detecting different stages, from mild manifestations of memory loss to advanced dementia. The method is positioned as a less invasive and more precise way to address a disease that impacts millions of people and their families worldwide.

Scientific Validation and International Projection

Days before the appearance of this study, an extensive review published in the journal Nature and shared by cardiologist Eric Topol reinforced the relevance of the p-tau217 protein as a determining biomarker for Alzheimer's. Led by Henrik Zetterberg, from the University of Gothenburg, along with Barbara Bendlin from the University of Wisconsin-Madison, the research was based on multiple works to support the hypothesis that plasma p-tau217 allows for accurately capturing relevant information about the neurodegenerative processes underlying Alzheimer's. The p-tau217 protein has established itself as an effective biomarker for detecting Alzheimer's at different stages, from mild memory loss to advanced dementia, facilitating a more precise and less invasive approach to the pathology (Illustrative Image Infobae) The article highlights that optimized biomolecular technologies enable the detection of molecules related to neuronal damage even in minute concentrations in blood. This not only expands the repertoire of non-invasive methods but also accelerates patients' access to specific treatments and clinical trials, strengthening precision medicine. According to the signing scientists, "biomarkers based on biofluids have transformed research and care for neurodegenerative diseases, providing information on the molecular basis of Alzheimer's disease and other neurodegenerative dementias." This advance impacts the possibility of guiding interventions long before the appearance of the first manifest clinical symptoms.

You can also read:A tool predicts the risk of Alzheimer's years before symptoms appear

The Key Role of Biomarkers in Personalized Medicine

The Pasqual Maragall Foundation, dedicated to promoting research on Alzheimer's, highlights the strategic function of biomarkers. According to its definition, "biomarkers are biological indicators used to measure and analyze normal bodily processes, pathological conditions, or responses to medical treatments." The role of these indicators is fundamental: they facilitate the early identification of Alzheimer's, long before the patient or their family members notice the first functional deterioration. In addition, they allow monitoring the evolution of the disease over time, as well as evaluating the efficacy of experimental or approved treatments. This information is essential to personalize therapeutic strategies and adjust resources according to the biological profile of each patient. The implementation of accessible methodologies, based on a simple blood analysis, can transform care for millions of people and mitigate the enormous socioeconomic impact that dementia causes in healthcare systems and family environments. Recent studies show that, by measuring p-tau217 in blood, doctors gain diagnostic precision and clinical confidence, decisive elements for timely treatment. New biomolecular technologies allow the identification in blood of molecules associated with neuronal damage even in minimal quantities, which makes it possible for the diagnosis to be faster and less invasive, accelerating patients' access to treatments and clinical trials (Illustrative Image Infobae)

The Global Challenge of Alzheimer's and the Paths That Are Opening

Early detection thus becomes the central axis of the battle against Alzheimer's, a disease whose burden falls on both the affected individuals and their families and caregivers. The current figure of 57 million cases not only implies a health burden, but also a human challenge of enormous scale. The WHO's projection for 2050 warns of an upward trend that demands effective, preventive, and sustained interventions. You may be interested in:
By possessing tools based on plasma biomarkers, medicine advances towards diagnosis before the clinical phase, allowing for earlier referral to treatments and containment programs. If the accuracy achieved by the p-tau217 analysis is consolidated in routine practice, millions of diagnoses can be made more quickly and less invasively. The evidence accumulated by research led in Europe and the United States legitimizes this path as reference for global medicine. The present and future of the approach to Alzheimer's will, in part, involve the implementation of these analytical methods and the integration of biomarkers into diagnostic and prognostic algorithms, increasingly directing attention towards individual needs and profiles.